Related Experiment Videos
Specific cytotoxic T lymphocytes in gene therapy
U Altenschmidt1, D Moritz, B Groner
1Institute for Experimental Cancer Research, Tumor Biology Center, Freiburg, Germany.
Journal of Molecular Medicine (Berlin, Germany)
|April 1, 1997
Summary
Genetically engineered T cells can target specific tumor cells by incorporating a chimeric zeta chain, overcoming limitations of natural T cell recognition for cancer therapy. Further strategies are needed to overcome tumor-induced immunosuppression for effective in vivo eradication.
Area of Science:
- Immunology
- Cancer Biology
- Genetic Engineering
Background:
- Cytotoxic T lymphocytes (CTLs) are crucial for recognizing and eliminating target cells expressing specific antigens via their T cell receptor (TCR).
- The therapeutic application of CTLs in cancer treatment is limited by their requirement to recognize tumor-specific antigens presented by MHC molecules.
- Tumor cells can evade immune detection and destruction through various mechanisms, including the secretion of immunosuppressive factors.
Purpose of the Study:
- To engineer CTLs with predetermined specificity for tumor cells, circumventing MHC restriction.
- To investigate the efficacy of genetically modified CTLs in recognizing and lysing target tumor cells.
- To explore strategies for overcoming tumor-induced immunosuppression to enhance in vivo anti-tumor immunity.
Main Methods:
- Genetic manipulation of the zeta component of the TCR to include an extracellular single-chain antibody domain, creating a chimeric zeta chain.
- Retroviral-mediated gene transduction to introduce chimeric zeta chain constructs into primary mouse T cells.
- Co-cultivation of engineered T cells with tumor cells and assessment of target cell recognition and lysis, including evaluation of tumor-secreted immunosuppressive factors.
Main Results:
- High gene transduction efficiency was achieved, resulting in primary T cells with engineered specificity for target cell recognition and lysis.
- The engineered T cells demonstrated the ability to recognize and lyse tumor cells independent of MHC restriction.
- Tumors were shown to secrete transforming growth factor beta (TGF-β), which suppresses lymphocyte activity.
Conclusions:
- Genetically engineered T cells expressing chimeric zeta chains can be endowed with predetermined specificity for tumor cells, offering a potential cancer immunotherapy approach.
- Overcoming MHC restriction broadens the applicability of T cell-based cancer therapy.
- A combination of engineered T cells and strategies to counteract tumor-induced immunosuppression, such as inhibiting TGF-β, is likely necessary for effective in vivo tumor eradication.